Therefore, taking into account the results described in the present work and despite the inhibition levels observed in our assays and the need for more studies, especially at the in-vitro and in-vivo levels, we consider that these compounds may have potential interest in the context of PD and can be new skeletons for further exploration in the medicinal chemistry of COMT inhibitors. The gene discussed is COMT; the disease is Parkinson disease.